Maseno Institutional Repository (IR) is a digital service that collects, preserves, and distributes digital material. Repositories are important tools for preserving an organization's legacy; they facilitate digital preservation and scholarly communication.
Communities in Maseno IR
Select a community to browse its collections.
Recently Added
-
Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries
(Public Library of Science, 2021-01-11)The RTS,S/ASO1E malaria vaccine is being piloted in three countries—Ghana, Kenya, and Malawi—as part of a coordinated evaluation led by the World Health Organization, with support from global partners. This study estimates ... -
Correction: Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries
(Public Library of Science, 2021-04-22)Cost estimates under additional vaccine price assumptions are not included in the main result Table (Table 3). Please view S4 Table,“Unit cost of continuing to vaccinate in pilot areas at various vaccine prices,” for results ... -
National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study
(Elsevier, 2022-01-21)Currently available live, oral rotavirus vaccines (LORVs) have significantly reduced severe rotavirus hospitalizations and deaths worldwide. However, LORVs are not as effective in low- and middle-income countries (LMIC) ... -
Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries
(Public Library of Science, 2022-06-23)Live oral rotavirus vaccines (LORVs) have significantly reduced rotavirus hospitalizations and deaths worldwide. However, LORVs are less effective in low- and middle-income countries (LMICs). Next-generation rotavirus ... -
Safety profile of the RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
(Taylor & Francis, 2019-10-03)A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study. 8922 children ...